Rhythm Pharmaceuticals Reports Growth and Expands Pipeline

Rhythm Pharmaceuticals ( (RYTM) ) has provided an announcement.

Rhythm Pharmaceuticals announced preliminary unaudited net revenues of $42 million for the fourth quarter and $130 million for the full year of 2024, marking significant growth driven by increased patient reimbursement and inventory growth in the U.S. The company is advancing its clinical pipeline with several ongoing and upcoming trials, including a Phase 3 trial for acquired hypothalamic obesity and a new Phase 2 trial for Prader-Willi syndrome. These developments are expected to drive further growth and provide transformative treatment opportunities for unmet medical needs, reflecting the company’s strategic focus on expanding its therapeutic impact in rare diseases.

More about Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases. Their main product, IMCIVREE® (setmelanotide), is an MC4R agonist approved by regulatory agencies in the U.S., Europe, and the UK for the treatment of obesity associated with specific genetic conditions.

YTD Price Performance: -3.66%

Average Trading Volume: 549,777

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $3.56B

For an in-depth examination of RYTM stock, go to TipRanks’ Stock Analysis page.